We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Notice for patisiran (Alnylam Australia Pty Ltd)
Active ingredients
patisiran
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Concentrate for solution for infusion
Indication
For the treatment of hereditary transthyretin mediated amyloidosis (hATTR amyloidosis) in patients with polyneuropathy
Therapeutic area
Neurological disorder